Healthcare
Kintor Pharmaceutical Limited(KNTPF)
Live Price
Offline$0.342
+0.00% today
Window Change
+27.42%
Window
May 29, 2026 → Jun 18, 2026
- Market Cap
- $1.16B
- Revenue Growth
- +536.8%
- EPS Growth
- -19.4%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kintor Pharmaceutical Limited (KNTPF) is a Healthcare stock with a market cap of $1.16B and listed on OTC. The stock last traded around $0.34 and up 27.4% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +536.8%, EPS growth of -19.4%, a dividend yield of 0.0%. What stands out right now is revenue +536.8%, EPS -19.4%, free cash flow 0.0% with operating margin -632.4% and ROIC -68.2%. Valuation already assumes a fairly strong business story at price/sales 35.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KNTPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+536.8% vs +7.6% peer median
Operating Margin
Below sector median
-632.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +536.8% and EPS is at -19.4%, with operating margin around -632.4%.
Benchmark Edge
KNTPF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KNTPF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KNTPF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KNTPF and SPY.
Company Overview
Kintor Pharmaceutical Limited
Other OTC
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
- Leadership
- Youzhi Tong
- IPO Date
- Dec 11, 2020
- Employees
- 168
- Street Address
- No. 20 Songbei Road
- Mailing
- Suzhou, 215123
- Region
- Suzhou, CN
- Reporting Currency
- USD
- Investor Line
- 86 51 2626 39909
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 35.5
- Price/Book
- 6.3
Growth
- Revenue
- +536.8%
- EPS
- -19.4%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- -79.3%
- Operating Margin
- -632.4%
- Net Margin
- -625.2%
- ROE
- -102.5%
- ROIC
- -68.2%
Balance Sheet
- Debt/Equity
- 0.47
- Current Ratio
- 0.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.